Clinical Trial Update: Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 trial evaluated the combination of capecitabine and GTI-2040 for renal cell carcinoma, including metastatic cases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Renal Cell Carcinoma Metastatic

Drugs mentioned

• Capecitabine (capecitabine)
• GTI-2040 (GTI-2040)

Snippet

Sponsor: Aptose Biosciences Inc. | Conditions: Carcinoma, Renal Cell, Metastases, Neoplasm | Phase 1, Phase 2 | Status: COMPLETED